Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anteris Technologies Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Depreciation & Amortization
-AU$2.8m
CAGR 3-Years
-32%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Depreciation & Amortization
-AU$6.8m
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
Depreciation & Amortization
-AU$2.2m
CAGR 3-Years
-34%
CAGR 5-Years
-48%
CAGR 10-Years
-26%
SDI Ltd
ASX:SDI
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Next Science Ltd
ASX:NXS
Depreciation & Amortization
-$1.1m
CAGR 3-Years
-17%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Depreciation & Amortization?
Depreciation & Amortization
-2.8m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Depreciation & Amortization amounts to -2.8m AUD.

What is Anteris Technologies Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-15%

Over the last year, the Depreciation & Amortization growth was -60%. The average annual Depreciation & Amortization growth rates for Anteris Technologies Ltd have been -32% over the past three years , -15% over the past five years .

Back to Top